elenestinib

Search documents
赛诺菲斥资超90亿美元收购罕见病疗法公司,创欧洲药企今年收购规模之最
Di Yi Cai Jing· 2025-06-02 09:54
Core Viewpoint - Sanofi has announced a $9.5 billion acquisition of Blueprint Medicines, marking the largest healthcare acquisition by a European pharmaceutical company this year, aimed at expanding its portfolio in rare immune diseases with the drug avapritinib [1][2]. Group 1: Acquisition Details - The acquisition includes avapritinib, the only approved drug globally for advanced systemic mastocytosis, which is a rare immune disease characterized by abnormal mast cell accumulation [1]. - Blueprint's stock surged over 26% following the announcement, while its Chinese partner, Basilea Pharmaceutica, saw a nearly 5% increase in share price [1]. - The deal is expected to enhance Sanofi's research pipeline in rare immune diseases [1]. Group 2: Financial Performance - Avapritinib generated $479 million in net revenue for Sanofi in 2024, with nearly $150 million in revenue in Q1 2025, reflecting a year-over-year growth of over 60% [2]. - In China, avapritinib has been approved and recommended as a first-line treatment in the first "Systemic Mastocytosis Diagnosis and Treatment Guidelines" [2]. Group 3: Future Prospects - The acquisition will also provide Sanofi with the next-generation systemic mastocytosis drug elenestinib and the highly selective oral wild-type KIT inhibitor BLU-808, which has potential applications in various immune diseases [2]. - Sanofi's CEO Paul Hudson indicated that this acquisition complements recent purchases of early-stage drugs and that the company retains significant capacity for further acquisitions [2].
95亿美元!赛诺菲收购Blueprint,加速罕见免疫疾病领域布局
生物世界· 2025-06-02 08:26
撰文丨王聪 编辑丨王多鱼 排版丨水成文 2025 年 6 月 2 日,法国制药巨头 赛诺菲 (Sanofi) 宣布收购美国生物制药上市公司 Blueprint Medicines , 以扩大自身在罕见免疫疾病领域的产品组合,并增添免疫学领域的早期研发管线, 交易总金 额高达 95 亿美元 。 根据收购条款,赛诺菲将在交易完成时以每股 129.00 美元的现金支付,股权价值约为 91 亿 美元,此 外,Blueprint 股东还将获得一份不可交易的或有价值权 (CVR) ,该权利持有人将有权在 BLU-808 未 来达到研发里程碑和监管里程碑时分别获得额外里程碑付款。因此,此次收购的总股权价值在完全稀释的 基础上约为 95 亿 美元。该收购预计在 2025 年第三季度完成。 此次收购对于赛诺菲的战略意义在于: 1、强化免疫学布局 : 2、商业化协同 : Blueprint 在过敏、皮肤和免疫领域的渠道资源,可加速赛诺菲免疫学产品落地。 3、财务影响 : 赛诺菲将获得 Blueprint 在 系统性肥大细胞增多症 (S ystemic Mastocytosis ) 领域的独家药物 Ayvakit/Ayvakyt ...
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
GlobeNewswire News Room· 2025-06-02 05:00
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have ...
Blueprint Medicines (BPMC) 2025 Conference Transcript
2025-05-07 17:00
Blueprint Medicines (BPMC) 2025 Conference May 07, 2025 12:00 PM ET Speaker0 Pleasure to welcome the next presenting company, Blueprint Medicines. Joining us here on stage is CEO, Kate Havlund, as well as Fuad Nimani, president and president of research and development. Thank you both for for being here. For all of you in the audience and those in the webcast, you know, this is this has been one of our top picks from soup to nuts, the company that developed drugs, got it to commercialization, and now is on ...
Blueprint Medicines(BPMC) - 2025 Q1 - Earnings Call Transcript
2025-05-01 13:02
Blueprint Medicines (BPMC) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Jenna Cohen - Vice President of Investor Relations and Global Business CommunicationsKate Haviland - President & CEOPhilina Lee - Chief Commercial OfficerBecker Hewes - Chief Medical OfficerMike Landsittel - Chief Financial OfficerLaura Prendergast - Vice PresidentChristina Rossi - Chief Operating OfficerPaul Jeng - Vice PresidentMichael Yee - Managing DirectorMark Aleynick - Biotechnology Equity ResearchReni Benj ...
Blueprint Medicines(BPMC) - 2025 Q1 - Earnings Call Presentation
2025-05-01 12:08
Blueprint Medicines Driving growth and innovation with operational excellence First quarter 2025 financial and operating results INTRODUCTION AYVAKIT PERFORMANCE Kate Haviland Chief Executive Officer Philina Lee, PhD Chief Commercial Officer PROGRESS May 1, 2025 First quarter 2025 financial and operating results Becker Hewes, MD Chief Medical Officer FINANCIAL RESULTS Mike Landsittel Chief Financial Officer 2 CLINICAL Forward-looking statements This presentation contains forward-looking statements within th ...
Blueprint Medicines(BPMC) - 2025 Q1 - Earnings Call Transcript
2025-05-01 12:00
Blueprint Medicines (BPMC) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 Good morning. My name is Angela Lang, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines' First Q twenty twenty five Earnings Release and Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. Jenna Cohen, you may begin your conference. Speaker1 Thank you, ...